(Q45795381)

English

Comparative effectiveness research using electronic health records: impacts of oral antidiabetic drugs on the development of chronic kidney disease

scientific article published on 24 February 2013

Comparative effectiveness research using electronic health records: impacts of oral antidiabetic drugs on the development of chronic kidney disease

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

Comparative effectiveness research using electronic health records: impacts of oral antidiabetic drugs on the development of chronic kidney disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

electronic health records

1 reference

based on heuristic

inferred from title

object named as

Edward Ewen

2

0 references

author name string

Andrew L Masica

1

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

Yahya A Daoud

3

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

Dunlei Cheng

4

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

Nora Franceschini

5

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

Rustam E Kudyakov

6

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

James R Bowen

7

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

Emily S Brouwer

8

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

Dennis Wallace

9

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

Neil S Fleming

10

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

Suzanne L West

11

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

publication date

24 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

Pharmacoepidemiology and Drug Safety

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

22

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

4

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

413-422

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

describes a project that uses

electronic health records

1 reference

based on heuristic

inferred from title

Economic costs of diabetes in the U.S. In 2007.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Comparative effectiveness of incident oral antidiabetic drugs on kidney function

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Electronic health records and quality of diabetes care

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Electronic health record use to classify patients with newly diagnosed versus preexisting type 2 diabetes: infrastructure for comparative effectiveness research and population health management

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Evaluating Medication Effects Outside of Clinical Trials: New-User Designs

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Comparative effectiveness of beta-blockers in elderly patients with heart failure

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Constructing inverse probability weights for marginal structural models

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Comparison of direct action of thiazolidinediones and glucocorticoids on renal podocytes: protection from injury and molecular effects

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Preventing microalbuminuria in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Reviewing the benefits of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in diabetic nephropathy--are they drug specific or class specific?

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Standards of medical care in diabetes--2011.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Oxidative stress and endothelium influenced by metformin in type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Factors associated with first-fill adherence rates for diabetic medications: a cohort study

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Importance of including early nonadherence in estimations of medication adherence

1 reference

https://api.crossref.org/works/10.1002%2FPDS.3413

21 January 2018

Identifiers

10.1002/PDS.3413

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

16 December 2017

http://europepmc.org/abstract/MED/23436488

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45795381&oldid=2082866408"